Revelation Partners

Revelation Partners, LLC is a private equity firm based in San Francisco that specializes in buyout, direct, and fund of fund investments, primarily focusing on late-stage companies in the healthcare sector. The firm invests in a range of healthcare verticals, including medical devices, biopharmaceuticals, healthcare information technology, and healthcare services. Typically, Revelation Partners invests between $5 million and $30 million but is also capable of larger investments in collaboration with limited partners. The firm is committed to providing capital and liquidity, which includes making secondary investments and purchasing stakes from existing investors seeking liquidity. Additionally, Revelation Partners often takes a majority stake in the companies it invests in and offers follow-on investments to support their growth.

Michael Boggs

Managing Partner

Fred Lee

Managing Director

Zachary R. Scott

Managing Partner

Suchira Sharma

Associate

39 past transactions

Dren Bio

Series B in 2022
Dren Bio is a biotechnology company with a portfolio of attractive projects focused on powerful protein engineering technologies for the depletion of cells, protein aggregates, and other disease-causing agents. It is a holding company business model aimed at creating value with multiple projects as stand-alone assets.

Vertos Medical

Venture Round in 2017
Vertos Medical is a healthcare company that offers medical devices used in the treatment of common spinal diseases. The company commercializes the percutaneous treatment for lumbar spinal stenosis (LSS). It also offers minimally invasive lumbar decompression devices for the treatment of various forms of LSS. The company offers its devices in the United States. Vertos Medical, Inc. was founded by Dr. Dave Solsberg and Dr. Don Schomer in 2005 and is headquartered in Aliso Viejo, California, USA.

Gravia

Series E in 2022
Gravie is a health insurance marketplace designed to help consumers choose and buy insurance, pay for it, and manage all health care expenses in one place. Gravie specializes in the fields of health insurance, health care, and employer benefits. It was founded in 2013 and headquartered in Minneapolis, Minnesota.

Providence Medical Technology

Venture Round in 2018
Providence Medical Technology is a privately-held medical device company focused on innovative solutions for cervical spinal conditions. The company has pioneered a proprietary approach to cervical fusion and has developed surgical instrumentation and implants that offer unique benefits to the $2 billion worldwide cervical spine market. The Providence family of products includes the DTRAX® Spinal Instrumentation System, CAVUX® intervertebral implants, and the ALLY® line of bone and facet screws. All products are shipped-sterile and single-use to maximize perioperative efficiency and ensure consistent quality and performance.

Endeavor BioMedicines

Series B in 2022
Endeavor BioMedicines is developing new treatments targeting the underlying causes of pulmonary fibrosis.

Genome Medical

Series B in 2020
Genome Medical, Inc. operates a platform that provides genetic consultation and medical consulting services to individuals. The company through its Genome Care Delivery technology platform provides genetic solutions in the areas of clinical care, such as cancer, cardio, proactive, reproductive, pediatric, and pharmacy. Genome Medical, Inc. was incorporated in 2016 and is based in South San Francisco, California.

Genome Medical

Private Placement in 2019
Genome Medical, Inc. operates a platform that provides genetic consultation and medical consulting services to individuals. The company through its Genome Care Delivery technology platform provides genetic solutions in the areas of clinical care, such as cancer, cardio, proactive, reproductive, pediatric, and pharmacy. Genome Medical, Inc. was incorporated in 2016 and is based in South San Francisco, California.

Aspen Neuroscience

Series B in 2022
Aspen Neuroscience, Inc. develops induced pluripotent stem cells to treat neurological conditions. Its products pipeline includes ANPD001, an autologous neuron replacement therapy in sporadic Parkinson disease; and ANPD002, a gene-edited autologous neuron replacement therapy for familial forms of Parkinson disease. The company was incorporated in 2018 and is based in San Diego, California.

Gravia

Series D in 2021
Gravie is a health insurance marketplace designed to help consumers choose and buy insurance, pay for it, and manage all health care expenses in one place. Gravie specializes in the fields of health insurance, health care, and employer benefits. It was founded in 2013 and headquartered in Minneapolis, Minnesota.

Evidation Health

Private Placement in 2020
Evidation Health is a provider of a health data analytics platform designed to collect and analyze continuous behavior data and healthcare information so as to create better health outcomes. Its platform turns raw, high-frequency everyday behavior data from sensors, devices, speech, video, and other sources into new knowledge about health and disease, that enable individuals and innovative companies to understand and influence the everyday behaviors. It was founded in 2012 and is headquartered in San Mateo, California.

NeuroPace

Private Equity Round in 2020
NeuroPace, Inc. designs, develops, manufactures, and markets implantable devices for the treatment of neurological disorders with responsive stimulation. It offers RNS System, a medical device that monitors and responds to brain activity. The company’s RNS System consists of a small implantable neuro stimulator that is connected to leads that are placed in up to two seizure onset areas. NeuroPace, Inc. was founded in 1997 and is based in Mountain View, California.

Arterys

Series C in 2020
Arterys is the market leader and the world's first internet platform for medical imaging. Its objective is to transform healthcare by transforming radiology. The Arterys platform is 100% web-based, AI-powered, and FDA-cleared, unlocking simple clinical solutions.

Singular Genomics

Venture Round in 2019
Singular Genomics is a venture capital-backed biotech company in La Jolla, California. It fosters a dynamic, fast-paced, results-oriented environment where they offer employees the opportunity to make a significant impact in a rapidly expanding company. Singular Genomics is inventing at the forefront of genomics, one of the world’s fastest-growing industries. The company is located in the center of the Biotech hub on the Torrey Mesa close to the Pacific Ocean and next door to prestigious institutions like the Salk Institute, Scripps, Sanford Burnham, and UCSD.

AcuFocus

Venture Round in 2014
Acufocus, Inc., a medical device company, engages in the research, development, and marketing of solutions for the treatment of presbyopia. The company develops KAMRA, a corner inlay for the treatment of near vision loss that allows patients to see near and intermediate objects clearly; and AcuTarget, a system that is used to guide surgeons on surgical placement of the KAMRA. Its products are used in eye care centers in the United States, Asia, and Europe. Acufocus, Inc. was founded in 2001 and is based in Irvine, California.

SPR Therapeutics

Series D in 2024
SPRA Therapeutics is a medical device company that is commercializing pain treatments utilizing its proprietary peripheral nerve stimulation (PNS) products. They are developing a pipeline of neurostimulation pain therapies that will exploit the same physiologic mechanism of action, proprietary technology, and clinical approach. The first product to be commercialized is the SMARTPATCHâ„¢ PNS System, which is a short-term, minimally invasive system that is simple to deliver and can be used for up to 30 days to stimulate electrically a peripheral nerve to relieve pain.

VitalConnect

Series F in 2023
VitalConnect is a wearable biosensor technology for wireless hospital and remote patient monitoring. VitalConnect leverages extensive expertise in biomedical engineering, data analytics, chip design, and mobile and cloud software to create technology that supports decision-making paradigms that achieve better health and economic outcomes. VitalConnect's products are designed for use in a broad range of inpatient and outpatient settings, such as hospital monitoring, post-discharge care, cardiac monitoring, and pharmaceutical solutions. The Vista Solution offers uninterrupted and continuous access to patient health through an online portal, monitoring 11 unique vital signs and providing predictive analytics. VitalPatch biosensor measures single-lead EKG, heart rate, heart rate variability, respiratory rate, body or skin temperature, body posture, fall detection, and activity [steps]. Together, Vista Solution 2.0 and the VitalPatch biosensor offer an elegant, best-in-class solution that increases patient mobility and comfort, provides oversight without additional caregiver burden, and enhances patient outcomes. Vista Solution also offers a predictive, comprehensive picture of patients through the integrated National Early Warning Score (NEWS) standard, providing clinicians' with the ability to optimize treatment for their patients.

Singular Genomics

Convertible Note in 2021
Singular Genomics is a venture capital-backed biotech company in La Jolla, California. It fosters a dynamic, fast-paced, results-oriented environment where they offer employees the opportunity to make a significant impact in a rapidly expanding company. Singular Genomics is inventing at the forefront of genomics, one of the world’s fastest-growing industries. The company is located in the center of the Biotech hub on the Torrey Mesa close to the Pacific Ocean and next door to prestigious institutions like the Salk Institute, Scripps, Sanford Burnham, and UCSD.

SetPoint Medical

Venture Round in 2021
SetPoint Medical Corporation, a clinical-stage bioelectronic medicine company, develops implantable neuromodulation devices for treating patients with debilitating inflammatory diseases. SetPoint Medical Corporation was formerly known as Innovative Metabolics Inc. and changed its name to SetPoint Medical Corporation in July 2008. The company was incorporated in 2006 and is based in Valencia, California.

IntelyCare

Series C in 2022
IntelyCare offers a digital workforce augmentation platform that combines a gig-model application with advanced data science to optimize staff resources and close the widening gap between workforce supply and demand. IntelyCare is revolutionizing the antiquated healthcare staffing market, filling nursing shifts at three times the industry average and giving post-acute facilities the tools to predict and manage staffing needs. The company’s engaging mobile app empowers nursing professionals with access to flexible, on-demand work opportunities, reducing burnout and attrition while increasing productivity.

SPR Therapeutics

Series D in 2021
SPRA Therapeutics is a medical device company that is commercializing pain treatments utilizing its proprietary peripheral nerve stimulation (PNS) products. They are developing a pipeline of neurostimulation pain therapies that will exploit the same physiologic mechanism of action, proprietary technology, and clinical approach. The first product to be commercialized is the SMARTPATCHâ„¢ PNS System, which is a short-term, minimally invasive system that is simple to deliver and can be used for up to 30 days to stimulate electrically a peripheral nerve to relieve pain.

HotSpot Therapeutics

Series C in 2021
HotSpot Therapeutics is a developer of a therapy platform designed to discover medicines and provide proper treatment. The company's platform helps to identify hotspots and locate pathway treatments for cancer, metabolic and rare diseases, leverages a database of hotspot structures, harnessing the power of data science in its multidisciplinary approach to drug discovery enabling patients to get treatment against several diseases.

ClearCorrect

Private Equity Round in 2016
ClearCorrect is the clear and simple choice. No wires. No brackets. Just clear, convenient comfort—every reason to smile. With ClearCorrect, your dentist or orthodontist can straighten your teeth using a series of clear, custom, removable aligners. Each aligner moves your teeth just a little bit at a time until you eventually get straight teeth.

Genome Medical

Series C in 2021
Genome Medical, Inc. operates a platform that provides genetic consultation and medical consulting services to individuals. The company through its Genome Care Delivery technology platform provides genetic solutions in the areas of clinical care, such as cancer, cardio, proactive, reproductive, pediatric, and pharmacy. Genome Medical, Inc. was incorporated in 2016 and is based in South San Francisco, California.

Click Therapeutics

Series B in 2021
Click Therapeutics, Inc. engineers, validates, develops, and commercializes digital therapeutics solutions to benefit people with unmet medical needs through cognitive and neurobehavioral modification. It develops and commercializes novel digital therapeutics for various indications, including smoking cessation, major depressive disorders, schizophrenia, insomnia, acute coronary syndrome, migraine, overactive bladder, chronic low back pain, and obesity. Click Therapeutics, Inc. was founded in 2012 and is based in New York, New York.

Nuvolo

Series C in 2021
Nuvolo Technologies Corporation provides a cloud-based enterprise asset management platform under the name ServiceNow. The company provides life-cycle management solutions for enterprise assets of clinics, laboratories, facilities, and manufacturers. Additionally, it offers implementation, support, tracking, reporting, and analytics solutions. The company has strategic partnerships with Atos, Fruition Partners, InSource, KPMG, and Unisys. Nuvolo Technologies Corporation was founded in 2013 and is based in Paramus, New Jersey with additional offices in London, United Kingdom; Sofia, Bulgaria; and Pune, India.

Evidation Health

Series D in 2020
Evidation Health is a provider of a health data analytics platform designed to collect and analyze continuous behavior data and healthcare information so as to create better health outcomes. Its platform turns raw, high-frequency everyday behavior data from sensors, devices, speech, video, and other sources into new knowledge about health and disease, that enable individuals and innovative companies to understand and influence the everyday behaviors. It was founded in 2012 and is headquartered in San Mateo, California.

Arcadia Solutions

Private Placement in 2019
Arcadia Healthcare Solutions is an EHR data aggregation and analytics technology company delivering managed care to ambulatory networks taking on value-based risk. Arcadia specializes in the integration of data from 30+ EHR platforms, enriching them with claims and operational data, and using that data to drive improvements in patient care quality, practice efficiency, and financial performance. Trusted by independent provider groups, health plans, and integrated delivery networks nationwide, with expertise in both fee-for-service optimization and value-based performance environments, Arcadia supports providers with the benchmark data, insights, and outsourced services to excel in the evolving landscape of American healthcare. Founded in 2002, Arcadia is headquartered outside Boston in Burlington, MA, with offices in Seattle and outside Chicago in Rockford, IL.

SomaLogic

Series A in 2020
SomaLogic operates as a protein biomarker discovery and clinical diagnostics company. It offers SOMAmers (Slow-Offrate Modified Aptamers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein; and SOMAscan that provides protein detection and equipment. The company’s SOMAmer/SOMAscan technology enables to discover protein biomarker signatures; drug discovery and development; and clinical diagnostics. Its products have applications in the diagnostics of various diseases in oncology, neurology, cardiovascular and metabolic disease, and other diseases and conditions. SomaLogic was founded in 1999 and is headquartered in Boulder, Colorado.

Syapse

Private Placement in 2020
Syapse works with leading health systems, life sciences companies, and regulators to accelerate real-world evidence to improve the outcomes of cancer patients. By bringing these organizations together into the Syapse Learning Health Network, Syapse has built one of the world’s largest networks dedicated to improving outcomes in cancer care through improved precision medicine. Syapse and its partners are working towards a future in which all cancer patients have access to the quality of care they need. The company was founded in 2008 and is headquartered in San Francisco, California.

Syapse

Series F in 2020
Syapse works with leading health systems, life sciences companies, and regulators to accelerate real-world evidence to improve the outcomes of cancer patients. By bringing these organizations together into the Syapse Learning Health Network, Syapse has built one of the world’s largest networks dedicated to improving outcomes in cancer care through improved precision medicine. Syapse and its partners are working towards a future in which all cancer patients have access to the quality of care they need. The company was founded in 2008 and is headquartered in San Francisco, California.

Arterys

Private Placement in 2020
Arterys is the market leader and the world's first internet platform for medical imaging. Its objective is to transform healthcare by transforming radiology. The Arterys platform is 100% web-based, AI-powered, and FDA-cleared, unlocking simple clinical solutions.

Providence Medical Technology

Private Placement in 2018
Providence Medical Technology is a privately-held medical device company focused on innovative solutions for cervical spinal conditions. The company has pioneered a proprietary approach to cervical fusion and has developed surgical instrumentation and implants that offer unique benefits to the $2 billion worldwide cervical spine market. The Providence family of products includes the DTRAX® Spinal Instrumentation System, CAVUX® intervertebral implants, and the ALLY® line of bone and facet screws. All products are shipped-sterile and single-use to maximize perioperative efficiency and ensure consistent quality and performance.

MISSION Therapeutics

Venture Round in 2020
Mission Therapeutics is a drug development company targeting the ubiquitin pathway for the treatment of kidney disease, neurodegenerative disease, rare mitochondrial diseases and fibrosis. The Company has built a leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging drug class that is attracting significant commercial interest in the area of protein homeostasis.

Bristol Hospice

Venture Round in 2023
Bristol Hospice programs are designed to promote quality and comprehensive services to our patients, families, and communities.It was formed in 2006, focusing on the delivery of hospice services in the geographic areas as identified in the company’s strategic plan.

Carrum Health

Series B in 2023
Healthcare is unreasonably complex and costly. At Carrum Health, they’re applying a common sense approach to simplify the payment model and produce greater value for employers and their employees. They do so by directly connecting progressive self-insured employers to top-quality regional healthcare providers through the industry’s first comprehensive bundled payment solution. Their innovative platform reimagines how care is paid for and delivered, improving the value of health benefits for employers and their members.

Vedanta Biosciences

Series E in 2023
Vedanta Biosciences is a developer of immunotherapies designed to treat immune-mediated and infectious diseases. The company's immunotherapies include a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing of rationally-defined bacterial consortia in powder form, enabling physicians to access live bacteria drug to treat autoimmune and inflammatory diseases easily. It was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Nouscom

Series C in 2023
Nouscom are a well established team that has worked together for many years in previous successful enterprises, including IRBM/Merck and Okairos, and are veterans in the field of oncolytic and genetic vaccines. The company is headquartered in Basel, Switzerland and has operations in Rome, Italy. The NousCom team is lead by experienced enterpreneurs that worked together for many years in previous successful enterprises, such as Okairos, under the leadership of Prof. Riccardo Cortese, who conceived the ideas behind those companies.

Bluesight

Series B in 2015
KitCheck is a provider of a cloud software platform used to offer automated hospital pharmacy kit processing and medication tracking. The company provides cloud-hosted software combined with IoT technology to reduce kit replenishment time by 72-96% while simultaneously delivering higher accuracy and eliminating errors. In addition, the Narc Check product streamlines recording, waste reconciliation, and billing for medications used in the operating room. Kit Check is used across hundreds of hospitals in the U.S. and Canada and tracks over 90% of all kit medication volume in the industry that is digitally tracked.